Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Advances in Microarray Technology

Carl Borrebaeck's Biography



Carl Borrebaeck, Professor and Deputy Vice Chancellor, Lund University

Prof. Carl Borrebaeck is chairman of the Department of Immunotechnology, Lund University and program Director of the Strategic Center for Translational Cancer Research – CREATE Health (www.createhealth.lth.se). He received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences and deputy vice chancellor of Lund University, with a special responsibility for its innovation system. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy. Prof. Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. He received his Doctor of Science (D.Sc.) in 1979. His research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB and SenzaGen AB.

Carl Borrebaeck Image

Deciphering Complex Serum Portraits for Personalized Medicine in Oncology

Wednesday, 28 March 2012 at 09:30

Add to Calendar ▼2012-03-28 09:30:002012-03-28 10:30:00Europe/LondonDeciphering Complex Serum Portraits for Personalized Medicine in OncologyAdvances in Microarray Technology in Edinburgh, ScotlandEdinburgh, ScotlandSELECTBIOenquiries@selectbiosciences.com

One of the driving forces in personalized medicine is the search for protein patterns that can be utilized for improved diagnosis, assessing the risk for tumor relapse and disease progression. We have designed and developed antibody microarray, a high-throughput technology for protein expression profiling, to the point where it is now generating data for improved diagnosis, patient stratification etc. as well as insights into disease biology. Several clinical studies have been performed, including analysis of serum/plasma proteomes from patients suffering from e.g. glioblastoma multiforme, pancreatic carcinoma, gastric adenocarcinoma, CLL, breast cancer, and SLE. The presentation will be focusing on diagnosis, prediction of disease progression and differential diagnosis of different cancers, based on affinity proteomics.


Add to Calendar ▼2012-03-28 00:00:002012-03-29 00:00:00Europe/LondonAdvances in Microarray TechnologyAdvances in Microarray Technology in Edinburgh, ScotlandEdinburgh, ScotlandSELECTBIOenquiries@selectbiosciences.com